Journal
NATURE COMMUNICATIONS
Volume 8, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms15497
Keywords
-
Categories
Funding
- Ontario Brain Institute
- Ontario government
- Canadian Institute of Health Research (CIHR) [MOP93775, MOP11260, MOP119429, MOP119430]
- US National Institutes of Health (NIH) [1R01DA033684]
- Fonds de Recherche du Quebec - Sante (FRQS) through Chercheur National salary award
- Fonds de Recherche du Quebec - Sante (FRQS) through Quebec Network on Suicide, Mood Disorders and Related Disorders
- Frederick Banting Graduate Scholarship
- Charles Best Canada Graduate Scholarship
- CIHR
- National Institute of Mental Health (NIMH)
- European Commission [LSHB-CT-2003-503428]
- Government of Alberta - Alberta Centennial Addiction and Mental Health Research Chair
- Canada Research Chair program
- National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
- Canadian Institutes of Health Research (CIHR)
- Brain Canada
- Lundbeck
- Bristol-Myers Squibb
- Pfizer
- Servier
Ask authors/readers for more resources
Antidepressants (ADs) are the most common treatment for major depressive disorder (MDD). However, only similar to 30% of patients experience adequate response after a single AD trial, and this variability remains poorly understood. Here, we investigated microRNAs (miRNAs) as biomarkers of AD response using small RNA-sequencing in paired samples from MDD patients enrolled in a large, randomized placebo-controlled trial of duloxetine collected before and 8 weeks after treatment. Our results revealed differential expression of miR-146a-5p, miR-146b-5p, miR-425-3p and miR-24-3p according to treatment response. These results were replicated in two independent clinical trials of MDD, a well-characterized animal model of depression, and post-mortem human brains. Furthermore, using a combination of bioinformatics, mRNA studies and functional in vitro experiments, we showed significant dysregulation of genes involved in MAPK/Wnt signalling pathways. Together, our results indicate that these miRNAs are consistent markers of treatment response and regulators of the MAPK/Wnt systems.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available